


# Fosun Newsletter

April 2014



## Stock Information

Stock Price (30/04/2014).....	HKD 9.38
52-week range.....	HKD 5.28-9.98
Shares (mn shares).....	6,422
Market Value (HKD bn).....	60.23



## News

### Fosun International announced a plan of Rights Issue

On 9 April, Fosun International announced a plan of Rights Issue, 39 Rights Shares for every 500 existing shares held by qualifying shareholders on the record date, at the price of HKD 9.76 per Rights Share. Number of Rights Share to be issued under this Rights Issue was 500,884,371, which will raise approximately HKD 4,888.6 million (before expenses). The underwriter of the Rights Issue is Fosun Holdings Limited, and the financial adviser is UBS. After the completion of the Rights Issue, the number of total issued shares of Fosun International will be enlarged from 6,421,594,500 to 6,922,478,871.

### BFC has become the permanent venue for The Bund Global Financial Summit

On 3 April, Shanghai Huangpu District Government signed a Memorandum of Strategic Cooperation with Yabuli China Entrepreneurs Forum, Fosun Group and The Bund Finance Center (BFC), announcing that BFC, Huangpu District, Shanghai, has become the permanent venue for the Bund Global Financial Summit.

### PE/VC List

On 18 April, China Venture Group (CVG) announced *CV Awards Annual China Venture Capital & Private Equity Investment Industry Ranking 2013* in Shanghai, Fosun ranked the 3<sup>rd</sup> among the top 30 of *The Best Chinese-funded Private Equity Investment Institutions 2013 by CVG* due to its excellent performance in PE industry; Mr. Liang Xinjun, Vice President and CEO of Fosun Group ranked 6<sup>th</sup> among top 10 of *The Best Chinese Private Equity Investors 2013* by CVG; furthermore, Star Capital was listed in *Top 10 of The Best Chinese Real Estate Funds 2013* by CVG.

## Industrial Operations

### Fosun Pharma

#### Fosun Pharma announced the completion of placing of H-shares

On 3 April, Fosun Pharma successfully allotted and issued an aggregate of 67,214,000 new H-shares at a placing price of HKD 26.51 per share. The net proceeds from the Placing amounted to approximately HKD 1,760.89 million.


The number of total issued shares of Fosun Pharma has increased to 2,311,611,364 shares as a result of the completion of the Placing. The number of total issued H Shares has increased to 403,284,000, with the representing percentage increased from 14.97% to 17.45% of total issued shares and the number of issued A Shares remains unchanged as 1,908,327,364, with the representing percentage decreased from 85.03% to 82.55% of total issued shares.

UBS AG Hong Kong Branch, J.P. Morgan Securities (Asia Pacific) Limited and CCB International Capital Limited serve as Placing Agents. Fosun Pharma intends to use the net proceeds from the Placing to replenish the working capital of itself and its subsidiaries, and finance potential mergers and acquisitions domestically or overseas.

#### Fosun Pharma was Granted Exclusive License by TB Alliance for TB Cure

On 23 April, Fosun Pharma announced that it has reached an agreement with TB Alliance after one-year negotiation and has been granted an exclusive license to develop, register, produce and sell PaMZ, a novel TB drug regimen developed by TB Alliance in China (including Hong Kong, Macau and Taiwan area). The Bill & Melinda Gates Foundation will contribute special funds to continue supporting the global development and clinical research on this drug.

The Global Alliance for TB Drug Development (TB Alliance) is an international non-profit organization dedicating to developing and researching drug regimens to fight tuberculosis. PaMZ, on which the cooperation is entered, is a novel TB drug regimen and shows the potential to be a shorter, easier, safer, and affordable treatment for both DS-TB and MDR-TB. The regimen has completed Phase 2 clinical trial and is now ready to enter a global Phase 3 clinical trial.



## Industrial Operations (Cont'd)

### Forte

	Attributable Sales GFA (sq.m.)	Attributable Sales Amount (RMB mn)
April 2014	43,216	597
January- April 2014	162,611	2,299

### Nanjing Nangang

Nanjing Iron & Steel announced its principal financial data for the year ended 31 December 2013 on 29 April 2014

Unit: Yuan Currency: RMB

	As at the end of 2013	As at the end of 2012		Increase/decrease as at the end of this year as compared with end of last year (%)	As at the end of 2011
		After Adjustment	Before Adjustment		
Total assets	36,710,721,889.97	34,218,812,772.52	34,218,181,454.96	7.28	34,379,630,962.04
Equity attributable to shareholders of the listed company	8,273,891,343.25	8,790,248,865.51	8,791,781,764.04	-5.87	9,739,414,347.46
Net cash flow from operating activities	2,987,749,973.53	1,996,906,980.13	1,980,267,141.34	49.62	-488,594,964.99
Operation revenue	26,822,513,596.21	32,032,052,246.61	32,032,052,246.61	-16.26	38,565,150,977.21
Net profit attributable to shareholders of the listed company	-618,450,299.26	-570,267,893.21	-561,325,793.68	NA	329,929,218.33
Net profit attributable to shareholders of the listed company net of non-recurring gain and lost	-517,143,741.86	-1,049,723,308.08	-1,049,723,308.08	NA	291,499,166.16
Weighted average return on equity (%)	-7.24	-6.15	-6.07	NA	3.34
Basic earnings per share (yuan / share)	-0.1596	-0.1471	-0.1448	NA	0.0851
Diluted earnings per share (yuan / share)	-0.1596	-0.1471	-0.1448	NA	0.0851

### Delisting risk warning on the shares of Nanjing Iron & Steel

Nanjing Iron & Steel issued *The Announcement in Relation to a Delisting Risk Warning to be Imposed on the Company Shares* on the same day. Since the audited net profit of Nanjing Iron & Steel for the year of 2012 and 2013 was negative, a delisting risk warning will be imposed on the shares of Nanjing Iron & Steel.

**Shareholders and potential investors are advised to exercise caution when dealing in the securities of Nanjing Iron & Steel.**

## Insurance


Premium income (thousand RMB)	Yong'an P&C Insurance	Pramerica Fosun Life Insurance
March 2014	706,901.7	5,439.8
January - March 2014	1,867,467.7	12,715.4

## Investment

### Fosun invested in 98% interests in IDERA Capital Management, Ltd.

On 26 March 2014, Fosun International signed a contract to acquire 98% interest in a Japanese company IDERA Capital Management, Ltd. ( "IDERA" ) with a consideration of 6.611 billion yen, and announced the completion of this acquisition on 15 May. IDERA is a very outstanding fund management and asset management company in Japan, with experienced management and capability in the whole industry chain of real-estate fund management and asset management. As at the end of March 2014, the total asset under management is 163.1 billion yen.

This transaction is also an important overseas investment for Fosun at the beginning of 2014 after the acquisition of Fosun Insurance Portugal and investment in German private bank BHF. After the completion of this acquisition, IDERA will play an important role as a real-estate investment platform of Fosun in Japan, and also, become a hub of connecting investment opportunities and investors in China, Japan and even over the world, it will help Fosun actively implementing the investment model of "Combing Chinese Momentum with Global Resources".



- Shareholding held percentages represent effective equity interests as at 31 December 2013.
- The Group held the equity interests in Yong'an P&C Insurance through the subsidiaries, Shanghai Fosun Industrial Technology Development Co., Ltd. ("Fosun Industrial Development") and Shanghai Fosun Industrial Investment Co., Ltd. ("Fosun Industrial Investment"), as to 16.18% and 3.75% respectively.
- Results of Forte real estate series fund are included.
- After the Reporting Period, the share incentive scheme and placing of H shares of Fosun Pharma were completed. As at 3 April 2014, the Group held 39.83% equity interests in Fosun Pharma.
- After the Reporting Period, the Group acquired additional shares in Yuyuan through its wholly-owned subsidiary. As at 21 February 2014, the Group held 28.06% equity interests in Yuyuan.
- The Group held 3.6% equity interests in Zhaojin Mining via its subsidiary Fosun Industrial Investment. As Yuyuan, 25% owned associate of the Group, also held 25.69% equity interests in Zhaojin Mining, the Group held totally 10.0% effective equity interests in Zhaojin Mining. As the Group holds 28.06% equity interests in Yuyuan through acquiring additional shares after the Reporting Period, the effective equity interests in Zhaojin Mining held by the Group as at 21 February 2014 was 10.8%.
- The Group held 17.41% shares of Giovanna Group Holdings Limited while Giovanna Group Holdings Limited indirectly wholly owns Focus Media.
- The Group held 9.96% equity interests in Folli Follie. In addition, Pramerica-Fosun China Opportunity Fund held 3.89% equity interests through its wholly-owned subsidiary.
- The Group held its A shares through its subsidiary, Nanjing Iron & Steel, and its wholly-owned subsidiary, Fosun Industrial Development, representing 0.66% and 0.35% of its total number of A shares respectively; the Company and its wholly-owned subsidiary Topper Link Limited held its H shares representing 9.15% of its total number of H shares. In addition, Pramerica-Fosun Opportunity Fund held its H shares representing 0.51% of its total number of H shares.
- The names of the Group's investment projects.
- The Group directly held 50% equity interests while the other 50% were held by Star Capital. As a result the Group held its effective equity interests of 64%.
- Shanghai Star Capital Investment Management Co., Ltd., general partner ("GP") of Star Capital.
- Tibet Fosun Investment Management Co., Ltd., GP of Fosun Chuanghong.
- Shanghai Fosun Capital Investment Management Co., Ltd., GP of Fosun Capital.
- Carlyle-Fosun (Shanghai) Equity Investment Management Co., Ltd., GP of Carlyle-Fosun.
- Fosun Equity Investment Ltd., GP of Pramerica-Fosun China Opportunity Fund.

## Contact Us

Fosun International Investor Relations Department  
 E-mail: [IR@fosun.com](mailto:IR@fosun.com), Direct Line: (8621) 2315 6838  
 Address: No.2, East Fuxing Rd, Shanghai

### Disclaimer

This document herewith includes forward-looking statements. All statements, other than statements of historical facts, that address activities, events or developments that Fosun International Limited and its portfolio companies expect or anticipate will or may occur in the future (including but not limited to projections, targets, estimates and business plans) are forward-looking statements. The company's actual results or developments may differ materially from those indicated by these forward-looking statements as a result of various factors and uncertainties, and other risk and factors beyond our control. In addition, the Company makes the forward-looking statements referred to herein as of today and undertakes no obligation to update these statements.